Упрощенная HTML-версия
F. Ansari // Pharmacoepidemiol. Drug. Saf. - 2000. — Vol. 9, № 7. —
P. 611-613.
311. Antibodies protect mice against challenge with tick-borne encephalitis virus
(TBEV)-infected macrophages / T. R. Kreil [et ai.] // Clin. Exp. Immunol. -
1997.-Vol. 110, № 3 . -P . 358-361.
312. Antibody prophylaxis and therapy for flavivirus encephalitis infections /
J. T. Roehrig [et al.] // Ann. N. Y. Acad. Sci. - 2001. - Vol. 951. - P. 286-297.
313. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients
infected with HIV type 1 / D.R. Kuritzkes [et al.] // J. Infect. Dis. - 2004. -
Vol. 189.-P . 286-290.
314. Antiviral effects of terpene compounds may be due to their immunomodulatory
properties / A. N. Narovlyansky [et al.] // ASM conference Immunity to bacterial,
viral, and protozoal pathogens. - Savannah, 2002. - P. 26-27.
315. Antibody responses against wild-type yellow fever virus and the 17D vaccine
strain: characterization with human monoclonal antibody fragments and
neutralization escape variants / S. Daffis [et al] // Virology. - 2005. - V. 337. -
P. 262-272.
316. Arras, C. Do specific hyperimmunoglobulins aggravate clinical course of tick-
borne encephalitis? [letter; comment] / C. Arras, R. Fescharek, J. P. Gregersen //
Lancet. -1996. - Vol. 347, № 9011. - P. 1331.
317. Arvin, A. M. Varicella-zoster virus / A. M. Arvin // Clin. Microbiol. Rev. - 1996.
Vol. 9 . -P . 361-381.
318. В cells and antibody play critical roles in the immediate defense o f disseminated
infection byWest Nile encephalitis virus / M. S. Diamond [et al.] // J. Virol. -2003 . -
Vol.77.-P. 2578-2586.
319. Baker, C. J. Intravenous immune globulin for the prevention o f nosocomial
infection in low-birth-weight neonates / C. J. Baker, М. E. Melish, R. T. Hall. //
N. Engl. J. Med. - 1992. - Vol. 327. - P. 213-219.
320. Ballow, M. Mechanisms of action of intravenous immune serum globulin in
autoimmune and inflammatory diseases / M. Ballow // J. Allergy Clin. Immunol. -
1997.-V o l. 100.-P . 151-171.
321. Borgia, G. HepeX-C (XTL Biopharmaceuticals) / G. Borgia// Curr. Opin. Investig.
Drugs. - 2004. - Vol. 5, № 8. - P. 892-897.
322. Bregenholt, S. Pathogen-specific recombinant human polyclonal antibodies:
biodefence applications / S. Bregenholt, J. Haurum // Expert Opin. Biol. Ther. -
2004.
- Vol. 4, № 3. - P. 387-396.
323. Broker, M. After a tick bite in a tick-borne encephalitis virus endemic area: current
positions about post-exposure treatment / М. Вгбкег, H. Kollaritsch // Vaccine. -
2008. - Vol. 26, № 7. - P. 863-868.
324. Bruss J. B. Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol
challenge model / J. B. Bruss, G. R. Siber // Clin. Diagn. Lab. Immunol. -
1999.-V o l. 6 . -P . 464-470.
325. Carter, P. J. Potent antibody therapeutics by design / P. J. Carter // Nat. Rev.
Immunol. - 2006. - Vol. 6, № 5. - P. 343-357.
326. Casadevall, A. Passive antibody therapies: progress and continuing challenges /
A. Casadevall // Clin. Immunol. - 1999. - Vol. 93. - P. 5-15.
327. Casadevall, A. Passive antibody therapy for infectious diseases / A. Casadevall,
220